G2TT
来源类型Working Paper
规范类型报告
DOI10.3386/w15723
来源IDWorking Paper 15723
Generic Utilization Rates, Real Pharmaceutical Prices, and Research and Development Expenditures
Joseph P. Cook; Graeme Hunter; John A. Vernon
发表日期2010-02-04
出版年2010
语种英语
摘要Generic utilization rates have risen substantially since the enactment of The Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman) in 1984. In the year Hatch-Waxman was enacted, generic utilization rates were 19 percent; in contrast, today, the generic utilization rate is approximately 70 percent. Striking a balance between access to existing medicines and access to yet-to-be-discovered (and developed) drugs, through research incentives, was the principal objective of this landmark legislation. However, given the current rate of generic utilization, it seems plausible, if not likely, that any balance achieved by the 1984 Act has since shifted away from research incentives and towards improved access, ceteris paribus. Among other factors, recent mandatory substitution laws in most states have driven up generic utilization rates. In the current paper, we employ semi-annual data from 1992 to 2008 to examine the link between generic utilization rates and real U.S. prescription drug prices. This link is important because previous research has identified a causal relationship between real drug prices in the U.S. and industry-level R&D investment intensity. We identify a statistically significant, positive relationship between generic utilization rates in the U.S. and real U.S. prescription drug prices. Specifically, we estimate an elasticity of real drug prices to generic utilization rates of -0.15. This finding, when coupled with previous empirical work on the determinants of pharmaceutical R&D intensity, suggests an elasticity of R&D to generic utilization rates of about 0.090. While the magnitude of this elasticity is modest, as theory would predict--the effect of greater generic erosion of brand sales at patent expiration is heavily discounted due to the long time horizon to generic erosion when an R&D project is in clinical development. However, because there has been a very substantial increase in generic utilization rates since 1984, the impact on R&D is nevertheless quite large. We explore this and other issues in the current paper.
主题Health, Education, and Welfare ; Health ; Other ; Law and Economics ; Industrial Organization
URLhttps://www.nber.org/papers/w15723
来源智库National Bureau of Economic Research (United States)
引用统计
资源类型智库出版物
条目标识符http://119.78.100.153/handle/2XGU8XDN/573397
推荐引用方式
GB/T 7714
Joseph P. Cook,Graeme Hunter,John A. Vernon. Generic Utilization Rates, Real Pharmaceutical Prices, and Research and Development Expenditures. 2010.
条目包含的文件
文件名称/大小 资源类型 版本类型 开放类型 使用许可
w15723.pdf(276KB)智库出版物 限制开放CC BY-NC-SA浏览
个性服务
推荐该条目
保存到收藏夹
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Joseph P. Cook]的文章
[Graeme Hunter]的文章
[John A. Vernon]的文章
百度学术
百度学术中相似的文章
[Joseph P. Cook]的文章
[Graeme Hunter]的文章
[John A. Vernon]的文章
必应学术
必应学术中相似的文章
[Joseph P. Cook]的文章
[Graeme Hunter]的文章
[John A. Vernon]的文章
相关权益政策
暂无数据
收藏/分享
文件名: w15723.pdf
格式: Adobe PDF
此文件暂不支持浏览

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。